In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), ...

Piper Sandler analyst Joseph Catanzaro lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $7.50 from $10 and keeps a Neutral ...

Truist Securities confirmed its positive stance on Iovance Biotherapeutics (NASDAQ:IOVA) shares, maintaining a Buy rating and a price target of $25.00. With the stock currently trading at $6.07, this ...

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. Could this be a great buying ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that ...

If you're looking for an under-the-radar stock that could deliver enormous gains in a defined time frame, the ...

A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...

Technical analysis for Iovance Biotherapeutics Inc. IOVA including support levels resistance levels and stop losses for IOVA ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Investors seem to be underestimating all of it. It's been a tough past four years for Iovance Biotherapeutics(NASDAQ: IOVA) ...